Telemetry Investments L.L.C. bought a new stake in SIGA Technologies, Inc. (NASDAQ:SIGA – Get Rating) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 14,299 shares of the company's stock, valued at approximately $147,000.

Other institutional investors also recently modified their holdings of the company. Wipfli Financial Advisors LLC bought a new position in shares of SIGA Technologies in the third quarter worth $50,000. UBS Group AG grew its stake in shares of SIGA Technologies by 30.3% in the second quarter. UBS Group AG now owns 4,596 shares of the company's stock worth $53,000 after purchasing an additional 1,070 shares during the last quarter. Cambridge Investment Research Advisors Inc. bought a new stake in shares of SIGA Technologies in the third quarter worth about $105,000. One Capital Management LLC bought a new stake in shares of SIGA Technologies in the third quarter worth about $111,000. Finally, Royal Bank of Canada boosted its position in SIGA Technologies by 338.6% during the 3rd quarter. Royal Bank of Canada now owns 10,771 shares of the company's stock valued at $111,000 after acquiring an additional 8,315 shares in the last quarter. 39.44% of the stock is owned by institutional investors.

SIGA Technologies Trading Up 3.1 %

SIGA Technologies stock traded up $0.16 during trading hours on Tuesday, hitting $5.39. 261,905 shares of the stock traded hands, compared to its average volume of 800,139. The firm's 50-day moving average price is $7.03 and its two-hundred day moving average price is $8.87. SIGA Technologies, Inc. has a one year low of $5.11 and a one year high of $26.99. The company has a market cap of $389.16 million, a PE ratio of 11.37 and a beta of 0.87.

SIGA Technologies Company Profile

(Get Rating)

SIGA Technologies, Inc is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The firm develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other dangerous viruses.

Further Reading

• Get a free copy of the StockNews.com research report on SIGA Technologies (SIGA)
• Healthcare Stocks With at Least 30 Years of Dividend Increases
• Coinbase Pops As SVB Crumbles To Dust
• Airlines Update Guidance, Shares Head For Different Destinations
• Is Academy Sports And Outdoors A Buy For 2023?
• Regional Bank Depositors Turn to Bank of America After SVB Fail

Receive News & Ratings for SIGA Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SIGA Technologies and related companies with MarketBeat.com's FREE daily email newsletter.